Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age

Immortal Time Bias in Observational Studies

(2021) Kabir Yadav et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis

(2020) Natalie A. Schwehr et al.   DRUGS & AGING

Long-standing multiple sclerosis neurodegeneration: volumetric MRI comparison to Parkinson’s disease, mild cognitive impairment and Alzheimer’s disease and elderly healthy controls

(2020) Dejan Jakimovski et al.   NEUROBIOLOGY OF AGING

Sex‐Specific Differences in Life Span Brain Volumes in Multiple Sclerosis

(2020) Dejan Jakimovski et al.   JOURNAL OF NEUROIMAGING

Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent

(2020) Marcus W. Koch et al.   JOURNAL OF NEUROLOGY

Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity

(2020) Anne-Laure Kaminsky et al.   JOURNAL OF NEUROLOGY

Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis

(2020) Tobias Monschein et al.   JOURNAL OF NEUROLOGY

Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score

(2020) Gabriel Bsteh et al.   EUROPEAN JOURNAL OF NEUROLOGY

The prevalence of MS in the United States

(2019) Mitchell T. Wallin et al.   NEUROLOGY

Epidemiology and treatment of multiple sclerosis in elderly populations

(2019) Caila B. Vaughn et al.   Nature Reviews Neurology

Cognitive Profiles of Aging in Multiple Sclerosis

(2019) Dejan Jakimovski et al.   Frontiers in Aging Neuroscience

Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60

(2019) Le H. Hua et al.   Multiple Sclerosis and Related Disorders

Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies

(2019) Marisa P McGinley et al.   Multiple Sclerosis Journal

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

(2018) Ludwig Kappos et al.   LANCET

Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60

(2018) Le H Hua et al.   Multiple Sclerosis Journal

Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60

(2018) Le H Hua et al.   Multiple Sclerosis Journal

Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium

(2018) Caila B Vaughn et al.   Multiple Sclerosis Journal

Ocrelizumab: a B-cell depleting therapy for multiple sclerosis

(2017) Dejan Jakimovski et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Defining secondary progressive multiple sclerosis

(2016) Johannes Lorscheider et al.   BRAIN

Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?

(2016) J. Bonenfant et al.   EUROPEAN JOURNAL OF NEUROLOGY

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

(2016) Ilya Kister et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors

(2016) Gabriel Bsteh et al.   Multiple Sclerosis Journal

Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors

(2016) Gabriel Bsteh et al.   Multiple Sclerosis Journal

The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?

(2015) D. M. Hartung et al.   NEUROLOGY

Stopping immunomodulatory medications in MS: Frequency, reasons and consequences

(2015) W.O. Tobin et al.   Multiple Sclerosis and Related Disorders

Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis

(2014) Manuel A. Friese et al.   Nature Reviews Neurology

Statistical cures and other fallacies

(2012) Gary R Cutter   Multiple Sclerosis Journal

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

The rising prevalence and changing age distribution of multiple sclerosis in Manitoba

(2010) R. A. Marrie et al.   NEUROLOGY

The Will Rogers phenomenon: the effect of different diagnostic criteria

(2009) Maria Pia Sormani   JOURNAL OF THE NEUROLOGICAL SCIENCES

Relapses in multiple sclerosis are age- and time-dependent

(2008) H Tremlett et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY